SCR-LIP-000231 · Claim · machine-readable JSON →

This review proposes AKR1C enzymes (AKR1C1-4) as a central biological pathway linking rare familial mutations (e.g., AKR1C1 L213Q segregating with lipedema across 3 generations, AKR1C2 Ser320PheTer2) and common regulatory polymorphisms (rs28571848, rs34477787) to lipedema through altered steroid hormone metabolism in gluteofemoral subcutaneous adipose tissue, with environmental endocrine disruptors and hormones converging on the same hereditary pathway.

Claim at a glance
Type
clinical association
Knowledge state
Emerging
Evidence certainty
low (GRADE)
Evidence
1 source(s)
Dates
2026-05-31 → 2026-05-31

Structured evidence, machine-compiled — not a verdict.

Auto-compiled by the Layer 1 surveillance loop; not yet human-reviewed. anthropic/claude-opus-4.8 · 2026-05-31

Evidence over time

2026From rare familial mutations to multifactorial disease: aldo-keto reductase 1C enzymes as a central biological pathway in lipedema — Vainberg et al. (2026) · consistent

Evidence (1)

Context (PECO)

Populationwomen with lipedema, familial or sporadic
Conditionlipedema
ExposureAKR1C1-4 mutations, polymorphisms, endocrine disruptors
Outcomealtered steroid metabolism linked to lipedema
Scopeauto-ingested from Layer 1 surveillance

Answers these questions

Gaps & caveats

Auto-ingested single source; not yet human-reviewed.

Change log